Human specific regulation of the telomerase reverse transcriptase gene

Genes

Volumn 7, Issue 7, 2016, Pages

  Zhang, Fan ^a   De Cheng, ^a   Wang, Shuwen ^a   Zhu, Jiyue ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Cancer; Chromatin; Telomerase; TERT; Transcriptional regulator

Indexed keywords

MAX PROTEIN; MYC PROTEIN; PROTEIN MAD1; SMAD PROTEIN; SMAD1 PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR E2F1; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; BINDING SITE; CANCER CELL; CANCER RISK; CELL DIFFERENTIATION; CHROMATIN CONDENSATION; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME REARRANGEMENT; CONTROLLED STUDY; DEACETYLATION; DNA METHYLATION; DNA SEQUENCE; DOWN REGULATION; ENZYME ACTIVITY; ENZYME REGULATION; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENE LOCUS; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; HUMAN CELL; INTRON; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN FUNCTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TELOMERE HOMEOSTASIS; TELOMERE SHORTENING; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION REGULATION;

EID: 84978496636     PISSN: None     EISSN: 20734425     Source Type: Journal    
DOI: 10.3390/genes7070030     Document Type: Review

References (91)

1. Venteicher, A. S.; Abreu, E. B.; Meng, Z.; McCann, K. E.; Terns, R. M.; Veenstra, T. D.; Terns, M. P.; Artandi, S. E. A human telomerase holoenzyme protein required for Cajal body localization and telomere synthesis. Science 2009, 323, 644-648. [CrossRef] [PubMed].
2. Cong, Y. S.; Wright, W. E.; Shay, J. W. Human telomerase and its regulation. Microbiol. Mol. Biol. Rev. 2002, 66, 407-425. [CrossRef] [PubMed].
3. Wright, W. E.; Shay, J. W. Telomere dynamics in cancer progression and prevention: Fundamental differences in human and mouse telomere biology. Nat. Med. 2000, 6, 849-851. [CrossRef] [PubMed].
4. Akincilar, S. C.; Unal, B.; Tergaonkar, V. Reactivation of telomerase in cancer. Cell Mol. Life Sci. 2016, 73, 1659-1670. [CrossRef] [PubMed].
5. Gomes, N. M.; Ryder, O. A.; Houck, M. L.; Charter, S. J.; Walker, W.; Forsyth, N. R.; Austad, S. N.; Venditti, C.; Pagel, M.; Shay, J. W.; et al. Comparative biology of mammalian telomeres: Hypotheses on ancestral states and the roles of telomeres in longevity determination. Aging Cell 2011, 10, 761-768. [CrossRef] [PubMed].
6. Horikawa, I.; Chiang, Y. J.; Patterson, T.; Feigenbaum, L.; Leem, S. H.; Michishita, E.; Larionov, V.; Hodes, R. J.; Barrett, J. C. Differential cis-regulation of human versus mouse TERT gene expression in vivo: Identification of a human-specific repressive element. Proc. Natl. Acad. Sci. USA 2005, 102, 18437-18442. [CrossRef] [PubMed].
7. Jia, W.; Wang, S.; Horner, J. W.; Wang, N.; Wang, H.; Gunther, E. J.; DePinho, R. A.; Zhu, J. A BAC transgenic reporter recapitulates in vivo regulation of human telomerase reverse transcriptase in development and tumorigenesis. FASEB J. 2011, 25, 979-989. [CrossRef] [PubMed].
8. Martin-Rivera, L.; Herrera, E. S.; Albar, J. P.; Blasco, M. A. A. Expression of mouse telomerase catalytic subunit in embryos and adult tissues. Proc. Natl. Acad. Sci. USA 1998, 95, 10471-10477. [CrossRef].
9. Prowse, K. R.; Greider, C. W. Developmental and tissue-specific regulation of mouse telomerase and telomere length. Proc. Natl. Acad. Sci. USA 1995, 92, 4818-4822. [CrossRef] [PubMed].
10. Greenberg, R. A.; Allsopp, R. C.; Chin, L.; Morin, G. B.; DePinho, R. A. Expression of mouse telomerase reverse transcriptase during development, differentiation and proliferation. Oncogene 1998, 16, 1723-1730. [PubMed].
11. Kipling, D.; Cooke, H. J. Hypervariable ultra-long telomeres in mice. Nature 1990, 347, 400-402. [CrossRef] [PubMed].
12. Singh, M.; Murriel, C. L.; Johnson, L. Genetically engineered mouse models: Closing the gap between preclinical data and trial outcomes. Cancer Res. 2012, 72, 2695-2700. [CrossRef] [PubMed].
13. Rangarajan, A.; Weinberg, R. A. Opinion: Comparative biology of mouse versus human cells: Modelling human cancer in mice. Nat. Rev. Cancer 2003, 3, 952-959. [CrossRef] [PubMed].
14. Aisner, D. L.; Wright, W. E.; Shay, J. W. Telomerase regulation: Not just flipping the switch. Curr. Opin. Genet. Dev. 2002, 12, 80-85. [CrossRef].
15. Takakura, M.; Kyo, S.; Kanaya, T.; Hirano, H.; Takeda, J.; Yutsudo, M.; Inoue, M. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res. 1999, 59, 551-557. [PubMed].
16. Wu, K. J.; Grandori, C.; Amacker, M.; Simon-Vermot, N.; Polack, A.; Lingner, J.; Dalla-Favera, R. Direct activation of TERT transcription by c-MYC. Nat. Genet. 1999, 21, 220-224. [PubMed].
17. Zhu, J.; Zhao, Y.; Wang, S. Chromatin and epigenetic regulation of the telomerase reverse transcriptase gene. Protein Cell 2010, 1, 22-32. [CrossRef] [PubMed].
18. Wang, S.; Zhu, J. The hTERT gene is embedded in a nuclease-resistant chromatin domain. J. Biol. Chem. 2004, 279, 55401-55410. [CrossRef] [PubMed].
19. Ducrest, A. L.; Amacker, M.; Mathieu, Y. D.; Cuthbert, A. P.; Trott, D. A.; Newbold, R. F.; Nabholz, M.; Lingner, J. Regulation of human telomerase activity: Repression by normal chromosome 3 abolishes nuclear telomerase reverse transcriptase transcripts but does not affect c-Myc activity. Cancer Res. 2001, 61, 7594-7602. [PubMed].
20. Wang, S.; Zhu, J. Evidence for a relief of repression mechanism for activation of the human telomerase reverse transcriptase promoter. J. Biol. Chem. 2003, 278, 18842-18850. [CrossRef] [PubMed].
21. Wang, S.; Hu, C.; Zhu, J. Transcriptional silencing of a novel hTERT reporter locus during in vitro differentiation of mouse embryonic stem cells. Mol. Biol. Cell. 2007, 18, 669-677. [CrossRef] [PubMed].
22. Bodnar, A. G.; Ouellette, M.; Frolkis, M.; Holt, S. E.; Chiu, C. P.; Morin, G. B.; Harley, C. B.; Shay, J. W.; Lichtsteiner, S.; Wright, W. E. Extension of life-span by introduction of telomerase into normal human cells. Science 1998, 279, 349-352. [CrossRef] [PubMed].
23. Wang, S.; Zhao, Y.; Hu, C.; Zhu, J. Differential repression of human and mouse TERT genes during cell differentiation. Nucleic Acids Res. 2009, 37, 2618-2629. [CrossRef] [PubMed].
24. Wilson, M. D.; Barbosa-Morais, N. L.; Schmidt, D.; Conboy, C. M.; Vanes, L.; Tybulewicz, V. L.; Fisher, E. M.; Tavare, S.; Odom, D. T. Species-specific transcription in mice carrying human chromosome 21. Science 2008, 322, 434-438. [CrossRef] [PubMed].
25. Horikawa, I.; Barrett, J. C. Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms. Carcinogenesis 2003, 24, 1167-1176. [CrossRef] [PubMed].
26. Xu, D.; Popov, N.; Hou, M.; Wang, Q.; Bjorkholm, M.; Gruber, A.; Menkel, A. R.; Henriksson, M. Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc. Natl. Acad. Sci. USA 2001, 98, 3826-3831. [CrossRef] [PubMed].
27. Zhao, Y.; Cheng, D.; Wang, S.; Zhu, J. Dual roles of c-Myc in the regulation of hTERT gene. Nucleic Acids Res. 2014, 42, 10385-10398. [CrossRef] [PubMed].
28. Lin, S. Y.; Elledge, S. J. Multiple tumor suppressor pathways negatively regulate telomerase. Cell 2003, 113, 881-889. [CrossRef].
29. Gunes, C.; Lichtsteiner, S.; Vasserot, A. P.; Englert, C. Expression of the hTERT gene is regulated at the level of transcriptional initiation and repressed by Mad1. Cancer Res. 2000, 60, 2116-2121. [PubMed].
30. Han, S.; Park, K.; Kim, H. Y.; Lee, M. S.; Kim, H. J.; Kim, Y. D. Expression of Mad1 protein inhibits proliferation of cancer cells and inversely correlated with Myc protein expression in primary gastric cancer. Oncol. Rep. 1999, 6, 569-574. [CrossRef] [PubMed].
31. Chou, C. K.; Lee, D. F.; Sun, H. L.; Li, L. Y.; Lin, C. Y.; Huang, W. C.; Hsu, J. M.; Kuo, H. P.; Yamaguchi, H.; Wang, Y. N.; et al. The suppression of MAD1 by AKT-mediated phosphorylation activates MAD1 target genes transcription. Mol. Carcinog. 2009, 48, 1048-1058. [CrossRef] [PubMed].
32. Crowe, D. L.; Nguyen, D. C.; Tsang, K. J.; Kyo, S. E2F-1 represses transcription of the human telomerase reverse transcriptase gene. Nucleic Acids Res. 2001, 29, 2789-2794. [CrossRef] [PubMed].
33. Ko, E.; Seo, H. W.; Jung, E. S.; Kim, B. H.; Jung, G. The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer. Oncotarget 2016, 7, 684-699. [CrossRef] [PubMed].
34. Coller, H. A.; Forman, J. J.; Legesse-Miller, A. "Myc'ed Messages": Myc Induces Transcription of E2F1 while Inhibiting Its Translation via a microRNA Polycistron. PLoS Genet. 2007, 3, 1329-1334. [CrossRef] [PubMed].
35. Zhang, Y.; Chen, L.; Yang, S.; Fang, D. E2F1: A potential negative regulator of hTERT transcription in normal cells upon activation of oncogenic c-Myc. Med. Sci. Monit. 2012, 18, RA12-RA15. [CrossRef] [PubMed].
36. Zhang, Y.; Zhang, A.; Shen, C.; Zhang, B.; Rao, Z.; Wang, R.; Yang, S.; Ning, S.; Mao, G.; Fang, D. E2F1 acts as a negative feedback regulator of c-Mycinduced hTERT transcription during tumorigenesis. Oncol. Rep. 2014, 32, 1273-1280. [PubMed].
37. Alonso, M. M.; Fueyo, J.; Yung, W. K.; Gomez-Manzano, C. E2F1 and telomerase: alliance in the dark side. Cell Cycle 2006, 5, 930-935. [CrossRef] [PubMed].
38. Alonso, M. M.; Fueyo, J.; Shay, J. W.; Aldape, K. D.; Jiang, H.; Lee, O. H.; Johnson, D. G.; Xu, J.; Kondo, Y.; Kanzawa, T.; et al. Expression of transcription factor E2F1 and telomerase in glioblastomas: Mechanistic linkage and prognostic significance. J. Natl. Cancer Inst. 2005, 97, 1589-1600. [CrossRef] [PubMed].
39. Alonso, M. M.; Fueyo, J.; Gomez-Manzano, C. Malignant Gliomas: Role of E2F1 Transcription Factor. Tumors Cent. Nervous Syst. 2011, 1, 89-97.
40. Yoo, Y. S.; Park, S.; Gwak, J.; Ju, B. G.; Oh, S. Involvement of transcription repressor Snail in the regulation of human telomerase reverse transcriptase (hTERT) by transforming growth factor-beta. Biochem. Biophys. Res. Commun. 2015, 465, 131-136. [CrossRef] [PubMed].
41. Kyo, S.; Takakura, M.; Fujiwara, T.; Inoue, M. Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci. 2008, 99, 1528-1538. [CrossRef] [PubMed].
42. Wang, S.; Hu, C.; Zhu, J. Distinct and temporal roles of nucleosomal remodeling and histone deacetylation in the repression of the hTERT gene. Mol. Biol. Cell. 2010, 21, 821-832. [CrossRef] [PubMed].
43. Daniel, M.; Peek, G. W.; Tollefsbol, T. O. Regulation of the human catalytic subunit of telomerase (hTERT). Gene 2012, 498, 135-146. [CrossRef] [PubMed].
44. Cong, Y. S.; Bacchetti, S. Histone deacetylation is involved in the transcriptional repression of hTERT in normal human cells. J. Biol. Chem. 2000, 275, 35665-35668. [CrossRef] [PubMed].
45. Cheng, D.; Zhao, Y.; Wang, S.; Jia, W.; Kang, J.; Zhu, J. Human Telomerase Reverse Transcriptase (hTERT) Transcription Requires Sp1/Sp3 Binding to the Promoter and a Permissive Chromatin Environment. J. Biol. Chem. 2015, 290, 30193-30203. [CrossRef] [PubMed].
46. Bechter, O. E.; Eisterer, W.; Dlaska, M.; Kühr, T.; Thaler, J. CpG island methylation of the hTERT promoter is associated with lower telomerase activity in B-cell lymphocytic leukemia. Exp. Hematol. 2002, 30, 26-33. [CrossRef].
47. Fan, Y.; Lee, S.; Wu, G.; Easton, J.; Yergeau, D.; Dummer, R.; Vogel, P.; Kirkwood, J. M.; Barnhill, R. L.; Pappo, A.; et al. Telomerase Expression by Aberrant Methylation of the TERT Promoter in Melanoma Arising in Giant Congenital Nevi. J. Investig. Dermatol. 2016, 136, 339-342. [CrossRef] [PubMed].
48. Deng, J.; Zhou, D.; Zhang, J.; Chen, Y.; Wang, C.; Liu, Y.; Zhao, K. Aberrant methylation of the TERT promoter in esophageal squamous cell carcinoma. Cancer Genet. 2015, 208, 602-609. [CrossRef] [PubMed].
49. Kochling, M.; Ewelt, C.; Furtjes, G.; Peetz-Dienhart, S.; Koos, B.; Hasselblatt, M.; Paulus, W.; Stummer, W.; Brokinkel, B. hTERT promoter methylation in pituitary adenomas. Brain Tumor Pathol. 2016, 33, 27-34. [CrossRef] [PubMed].
50. Mathew, R.; Jia, W.; Sharma, A.; Zhao, Y.; Clarke, L. E.; Cheng, X.; Wang, H.; Salli, U.; Vrana, K. E.; Robertson, G. P.; et al. Robust activation of the human but not mouse telomerase gene during the induction of pluripotency. FASEB J. 2010, 24, 2702-2715. [CrossRef] [PubMed].
51. Atkinson, S. P.; Hoare, S. F.; Glasspool, R. M.; Keith, W. N. Lack of telomerase gene expression in alternative lengthening of telomere cells is associated with chromatin remodeling of the hTR and hTERT gene promoters. Cancer Res. 2005, 65, 7585-7590. [PubMed].
52. Zinn, R. L.; Pruitt, K.; Eguchi, S.; Baylin, S. B.; Herman, J. G. hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site. Cancer Res. 2007, 67, 194-201. [CrossRef] [PubMed].
53. Kyo, S.; Takakura, M.; Taira, T.; Kanaya, T.; Itoh, H.; Yutsudo, M.; Ariga, H.; Inoue, M. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res. 2000, 28, 669-677. [CrossRef] [PubMed].
54. Kyo, S.; Takakura, M.; Kanaya, T.; Zhuo, W.; Fujimoto, K.; Nishio, Y.; Orimo, A.; Inoue, M. Estrogen activates telomerase. Cancer Res. 1999, 59, 5917-5921. [PubMed].
55. Kondoh, K.; Tsuji, N.; Asanuma, K.; Kobayashi, D.; Watanabe, N. Inhibition of estrogen receptor beta-mediated human telomerase reverse transcriptase gene transcription via the suppression of mitogen-activated protein kinase signaling plays an important role in 15-deoxy-Delta(12, 14)-prostaglandin J(2)-induced apoptosis in cancer cells. Exp. Cell. Res. 2007, 313, 3486-3496. [PubMed].
56. Grasselli, A.; Nanni, S.; Colussi, C.; Aiello, A.; Benvenuti, V.; Ragone, G.; Moretti, F.; Sacchi, A.; Bacchetti, S.; Gaetano, C.; et al. Estrogen receptor-alpha and endothelial nitric oxide synthase nuclear complex regulates transcription of human telomerase. Circ. Res. 2008, 103, 34-42. [CrossRef] [PubMed].
57. Veldman, T.; Liu, X.; Yuan, H.; Schlegel, R. Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Proc. Natl. Acad. Sci. USA 2003, 100, 8211-8216. [CrossRef] [PubMed].
58. Katzenellenbogen, R. A.; Vliet-Gregg, P.; Xu, M.; Galloway, D. A. NFX1-123 increases hTERT expression and telomerase activity posttranscriptionally in human papillomavirus type 16 E6 keratinocytes. J. Virol. 2009, 83, 6446-6456. [CrossRef] [PubMed].
59. Horn, S.; Figl, A.; Rachakonda, P. S.; Fischer, C.; Sucker, A.; Gast, A.; Kadel, S.; Moll, I.; Nagore, E.; Hemminki, K.; et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013, 339, 959-961. [CrossRef] [PubMed].
60. Borah, S.; Xi, L.; Zaug, A. J.; Powell, N. M.; Dancik, G.; Cohen, S. B.; Costello, J. C.; Theodorescu, D.; Cech, T. R. TERT promoter mutations and telomerase reactivation in urothelial cancer. Science 2015, 347, 1006-1010. [CrossRef] [PubMed].
61. Muzza, M.; Colombo, C.; Rossi, S.; Tosi, D.; Cirello, V.; Perrino, M.; de Leo, S.; Magnani, E.; Pignatti, E.; Vigo, B.; et al. Telomerase in differentiated thyroid cancer: Promoter mutations, expression and localization. Mol. Cell Endocrinol. 2015, 399, 288-295. [CrossRef] [PubMed].
62. Zagni, C.; Chiacchi, U.; Rescifina, A. Histone Methyltransferase Inhibitors: Novel Epigenetic Agents for Cancer Treatment. Curr. Med. Chem. 2013, 20, 167-185. [CrossRef] [PubMed].
63. Xi, L.; Schmidt, J. C.; Zaug, A. J.; Ascarrunz, D. R.; Cech, T. R. A novel two-step genome editing strategy with CRISPR-Cas9 provides new insights into telomerase action and TERT gene expression. Genome Biol. 2015, 16, 231-247. [CrossRef] [PubMed].
64. Bell, R. J.; Rube, H. T.; Kreig, A.; Mancini, A.; Fouse, S. D.; Nagarajan, R. P.; Choi, S.; Hong, C.; He, D.; Pekmezci, M.; et al. Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science 2015, 348, 1036-1039.
65. Stern, J. L.; Theodorescu, D.; Vogelstein, B.; Papadopoulos, N.; Cech, T. R. Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers. Genes Dev. 2015, 29, 2219-2224. [CrossRef] [PubMed].
66. Li, Y.; Zhou, Q. L.; Sun, W.; Chandrasekharan, P.; Cheng, H. S.; Ying, Z.; Lakshmanan, M.; Raju, A.; Tenen, D. G.; Cheng, S. Y.; et al. Non-canonical NF-kappaB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation. Nat. Cell Biol. 2015, 17, 1327-1338. [CrossRef] [PubMed].
67. Huang, F. W.; Bielski, C. M.; Rinne, M. L.; Hahn, W. C.; Sellers, W. R.; Stegmeier, F.; Garraway, L. A.; Kryukov, G. V. TERT promoter mutations and monoallelic activation of TERT in cancer. Oncogenesis 2015. [CrossRef] [PubMed].
68. Bojesen, S. E.; Pooley, K. A.; Johnatty, S. E.; Beesley, J.; Michailidou, K.; Tyrer, J. P.; Edwards, S. L.; Pickett, H. A.; Shen, H. C.; Smart, C. E.; et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat. Genet. 2013, 45, 371-384. [CrossRef] [PubMed].
69. Wu, H.; Qiao, N.; Wang, Y.; Jiang, M.; Wang, S.; Wang, C.; Hu, L. Association between the telomerase reverse transcriptase (TERT) rs2736098 polymorphism and cancer risk: evidence from a case-control study of non-small-cell lung cancer and a meta-analysis. PLoS ONE 2013. [CrossRef] [PubMed].
70. Zhang, C.; Tian, Y. P.; Wang, Y.; Guo, F. H.; Qin, J. F.; Ni, H. hTERT rs2736098 genetic variants and susceptibility of hepatocellular carcinoma in the Chinese population: A case-control study. Hepatobiliary Pancreat Dis. Int. 2013, 12, 74-79. [CrossRef].
71. Zhang, X. J.; Xu, Z.; Gong, Y. L.; Tang, C. J.; Chen, J. F. Association of TERT rs2736098 polymorphism with cancer risk: A meta-analysis. Asian Pac. J. Cancer Prev. 2012, 13, 4943-4946. [CrossRef].
72. Zhou, P.; Wei, L.; Xia, X.; Shao, N.; Qian, X.; Yang, Y. Association between telomerase reverse transcriptase rs2736100 polymorphism and risk of glioma. J. Surg. Res. 2014, 191, 156-160. [CrossRef] [PubMed].
73. Wei, R.; Cao, L.; Pu, H.; Wang, H.; Zheng, Y.; Niu, X.; Weng, X.; Zhang, H.; Favus, M. J.; Zhang, L.; et al. TERT Polymorphism rs2736100-C Is Associated with EGFR Mutation-Positive Non-Small Cell Lung Cancer. Clin. Cancer Res. 2015, 21, 5173-5180. [CrossRef] [PubMed].
74. Kinnersley, B.; Migliorini, G.; Broderick, P.; Whiffin, N.; Dobbins, S. E.; Casey, G.; Hopper, J.; Sieber, O.; Lipton, L.; Kerr, D. J.; et al. The TERT variant rs2736100 is associated with colorectal cancer risk. Br. J. Cancer 2012, 107, 1001-1008. [CrossRef] [PubMed].
75. Lan, Q.; Cawthon, R.; Gao, Y.; Hu, W.; Hosgood, H. D., 3rd; Barone-Adesi, F.; Ji, B. T.; Bassig, B.; Chow, W. H.; Shu, X.; et al. Longer telomere length in peripheral white blood cells is associated with risk of lung cancer and the rs2736100 (CLPTM1L-TERT) polymorphism in a prospective cohort study among women in China. PLoS ONE 2013. [CrossRef].
76. Kote-Jarai, Z.; Saunders, E. J.; Leongamornlert, D. A.; Tymrakiewicz, M.; Dadaev, T.; Jugurnauth-Little, S.; Ross-Adams, H.; Al Olama, A. A.; Benlloch, S.; Halim, S.; et al. Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Hum. Mol. Genet. 2013. [CrossRef].
77. Batista, R.; Cruvinel-Carloni, A.; Vinagre, J.; Peixoto, J.; Catarino, T. A.; Campanella, N. C.; Menezes, W.; Becker, A. P.; de Almeida, G. C.; Matsushita, M. M.; et al. The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism. Int. J. Cancer 2016, 414-423. [CrossRef] [PubMed].
78. Rachakonda, P. S.; Hosen, I.; de Verdier, P. J.; Fallah, M.; Heidenreich, B.; Ryk, C.; Wiklund, N. P.; Steineck, G.; Schadendorf, D.; Hemminki, K.; et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc. Natl. Acad. Sci. USA 2013, 110, 17426-17431. [CrossRef] [PubMed].
79. Huang, F. W.; Hodis, E.; Xu, M. J.; Kryukov, G. V.; Chin, L.; Garraway, L. A. Highly Recurrent TERT Promoter Mutations in Human Melanoma. Science 2013, 339, 957-958. [CrossRef] [PubMed].
80. Simon, M.; Hosen, I.; Gousias, K.; Rachakonda, S.; Heidenreich, B.; Gessi, M.; Schramm, J.; Hemminki, K.; Waha, A.; Kumar, R. TERT promoter mutations: A novel independent prognostic factor in primary glioblastomas. Neuro-Oncol. 2015, 17, 45-52. [CrossRef] [PubMed].
81. Vinagre, J.; Almeida, A.; Populo, H.; Batista, R.; Lyra, J.; Pinto, V.; Coelho, R.; Celestino, R.; Prazeres, H.; Lima, L.; et al. Frequency of TERT promoter mutations in human cancers. Nat. Commun. 2013. [CrossRef] [PubMed].
82. Mosrati, M. A.; Malmström, A.; Lysiak, M.; Krysztofiak, A.; Hallbeck, M.; Milos, P.; Hallbeck, A.-L. TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma. Oncotarget 2015, 6, 16663-16673. [CrossRef] [PubMed].
83. Nencha, U.; Rahimian, A.; Giry, M.; Sechi, A.; Mokhtari, K.; Polivka, M.; Schmitt, Y.; di Stefano, A. L.; Alentorn, A.; Labussiere, M.; et al. TERT promoter mutations and rs2853669 polymorphism: Prognostic impact and interactions with common alterations in glioblastomas. J. Neurooncol. 2016, 126, 441-446. [CrossRef] [PubMed].
84. Hosen, I.; Rachakonda, P. S.; Heidenreich, B.; Sitaram, R. T.; Ljungberg, B.; Roos, G.; Hemminki, K.; Kumar, R. TERT promoter mutations in clear cell renal cell carcinoma. Int. J. Cancer 2015, 136, 2448-2452. [CrossRef] [PubMed].
85. Catarino, R.; Araujo, A.; Coelho, A.; Gomes, M.; Nogueira, A.; Lopes, C.; Medeiros, R. M. Prognostic significance of telomerase polymorphism in non-small cell lung cancer. Clin. Cancer Res. 2010, 16, 3706-3712. [CrossRef] [PubMed].
86. Sheng, X.; Tong, N.; Tao, G.; Luo, D.; Wang, M.; Fang, Y.; Li, J.; Xu, M.; Zhang, Z.; Wu, D. TERT polymorphisms modify the risk of acute lymphoblastic leukemia in Chinese children. Carcinogenesis 2013, 34, 228-235. [CrossRef] [PubMed].
87. Carvajal-Carmona, L. G.; O'Mara, T. A.; Painter, J. N.; Lose, F. A.; Dennis, J.; Michailidou, K.; Tyrer, J. P.; Ahmed, S.; Ferguson, K.; Healey, C. S.; et al. Candidate locus analysis of the TERT-CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk. Hum. Genet. 2015, 134, 231-245. [CrossRef] [PubMed].
88. Scherf, D. B.; Sarkisyan, N.; Jacobsson, H.; Claus, R.; Bermejo, J. L.; Peil, B.; Gu, L.; Muley, T.; Meister, M.; Dienemann, H.; et al. Epigenetic screen identifies genotype-specific promoter DNA methylation and oncogenic potential of CHRNB4. Oncogene 2013, 32, 3329-3338. [CrossRef] [PubMed].
89. Zhao, Y.; Wang, S.; Popova, E. Y.; Grigoryev, S. A.; Zhu, J. Rearrangement of upstream sequences of the hTERT gene during cellular immortalization. Genes Chromosomes Cancer 2009, 48, 963-974. [CrossRef] [PubMed].
90. Cobrinik, D.; Ostrovnaya, I.; Hassimi, M.; Tickoo, S. K.; Cheung, I. Y.; Cheung, N. K. Recurrent pre-existing and acquired DNA copy number alterations, including focal TERT gains, in neuroblastoma central nervous system metastases. Genes Chromosomes Cancer 2013, 52, 1150-1166. [CrossRef] [PubMed].
91. Peifer, M.; Hertwig, F.; Roels, F.; Dreidax, D.; Gartlgruber, M.; Menon, R.; Kramer, A.; Roncaioli, J. L.; Sand, F.; Heuckmann, J. M.; et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature 2015, 526, 700-704. [CrossRef] [PubMed].